Vaccine Russian Roulette?

[RightWireReport]

Time – Russia on Tuesday became the first country to officially register a coronavirus vaccine and declare it ready for use, despite international skepticism. President Vladimir Putin said that one of his daughters has already been inoculated. The Russian leader added that one of his two adult daughters had received two shots of the vaccine. “She has taken part in the experiment,” Putin said.

Putin said that his daughter had a temperature of 38 degrees Celsius (100.4 Fahrenheit) on the day of the first vaccine injection, and then it dropped to just over 37 degrees (98.6 Fahrenheit) on the following day. After the second shot, she again had a slight increase in temperature, but then it was all over. “She’s feeling well and has a high number of antibodies,” Putin added.

Speaking at a government meeting Tuesday, Putin said that the vaccine has undergone proper testing and is safe. Russian officials have said that large-scale production of the vaccine will start in September, and mass vaccination may begin as early as October 2020.

Indonesia, on Tuesday, launched human trials of a Chinese-made coronavirus vaccine with some 1,600 volunteers slated to take part in the six-month study. The vaccine candidate, produced by Sinovac Biotech, is among just a few in the world to enter Phase 3 clinical trials or large-scale testing on humans – the last step before regulatory approval. The treatment, known as CoronaVac, is already being tested on 9,000 health workers in Brazil, the second-hardest-hit country in the coronavirus pandemic after the United States.

SAUDI Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China’s CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday. Last month, CanSino’s co-founder said the company was in talks with Russia, Brazil, Chile, and Saudi Arabia to launch a Phase III trial of the vaccine candidate, Ad5-nCOV. Saudi Arabia plans to test the vaccine alongside a placebo on 5,000 volunteers and is currently preparing trials in the cities of Riyadh, Dammam, and Mecca, Saudi state news agency SPA said on Saturday. No COVID-19 vaccine has been approved for commercial use.
What is the US doing? The Department of Health & Human ServicesOperation Warp Speed (OWS) aims to deliver 300 million doses of a safe, effective vaccine for COVID-19 by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (collectively known as countermeasures).

Moderna is the first company to begin its Phase 3 clinical trials of a coronavirus vaccine in the United States. The trial started the morning of July 27 and intends to enroll in 30,000 study subjects. The company has said it’s “on track to complete enrollment in September.” Moderna won’t make that 30,000 in September if they continue at the rate of the first two weeks, but it’s likely the speed of enrollment will ramp up, since as of Friday only 54 of the study’s 89 sites were operating, according to the company’s email to its researchers. Moderna’s numbers did increase significantly from the first week of the trial to the second week. Even if Moderna does reach its goal of full enrollment during the month of September, the company still won’t have a vaccine on the market by Election Day, infectious disease experts say.


So there are many Coronavirus vaccines in the pipeline. Just how many? BBC – says research is happening at breakneck speed. About 140 are in early development, and around two dozen are now being tested on people in clinical trials. But this list is growing. This tracker lists COVID-19 vaccine candidates currently in Phase 1-3 trials, as well as major candidates in pre-clinical stages of development and research. Information will be updated weekly. Here is a current snapshot for reference.

Candidate	Sponsor	Trial Phase	Institution	Funding
Inactivated vaccine	Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Phase 3	Henan Provincial Center for Disease Control and Prevention	Ministry of Science and Technology, China
CoronaVac	Sinovac	Phase 3	Sinovac Research and Development Co., Ltd.	Sinovac Research and Development Co., Ltd.
mRNA-1273	Moderna	Phase 3	Kaiser Permanente Washington Health Research Institute	Operation Warp Speed; NIAID, BARDA ($483 million)
Bacillus Calmette-Guerin (BCG) live-attenuated vaccine	University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital	Phase 2/3	University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital	Murdoch Children’s Research Institute; UMC Utrecht
AZD1222	The University of Oxford; AstraZeneca; IQVIA	Phase 2/3	The University of Oxford, the Jenner Institute	Operation Warp Speed; UK Ministry of Health; The University of Oxford; BARDA
BNT162	Pfizer, BioNTech	Phase 2/3	Multiple study sites in Europe and North America	Pfizer; BioNTech
Ad5-nCoV	CanSino Biologics	Phase 2	Tongji Hospital; Wuhan, China	CanSino Biologics
Adjuvant recombinant vaccine candidate	Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences	Phase 2
ZyCoV-D	Zydus Cadila	Phase 2	Zydus Cadila
Covaxin	Bharat Biotech; National Institute of Virology	Phase 2
BBIBP-CorV	Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Phase 1/2	Henan Provincial Center for Disease Control and Prevention	Ministry of Science and Technology, China
GX-19	Genexine	Phase 1/2		GenexineGenexine
Gam-COVID-Vac	Gamaleya Research Institute, Acellena Contract Drug Research and Development	Phase 1/2	Various	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Self-amplifying RNA vaccine	Imperial College London	Phase 1/2	Imperial College London	UK Secretary of State for Health; UK Secretary of State for Business, Energy and Industrial Strategy
LUNAR-COV19	Arcturus Therapeutics and Duke-NUS Medical School	Phase 1/2	Duke-NUS Medical School, Singapore	Arcturus
INO-4800	Inovio Pharmaceuticals	Phase 1	Center for Pharmaceutical Research, Kansas City. Mo.; University of Pennsylvania, Philadelphia	Inovio Pharmaceuticals
mRNA-based vaccine	CureVac	Phase 1	CureVac	CureVac; German federal government
SCB-2019	GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax	Phase 1	Linear Clinical Research (Australia)	CEPI
COVAX-19	Vaxine Pty Ltd.	Phase 1	Royal Adelaide Hospital	NIAID
NVX-CoV2373	Novavax	Phase 1	Novavax	Novavax, CEPI, Department of Defense ($60 million)
Plant-based adjutant COVID-19 vaccine candidate	Medicago; GSK; Dynavax	Phase 1	Medicago	Medicago
Molecular clamp vaccine	CSL; The University of Queensland	Phase 1		CEPI; CSL
bacTRL-Spike	Symvivo	Pre-clinical	Symvivo Corporation	Symvivo Corporation
PittCoVacc	UPMC/University of Pittsburgh School of Medicine	Pre-clinical	University of Pittsburgh	CEPI
V591	University of Pittsburgh’s Center for Vaccine Research	Pre-clinical	University of Pittsburgh; Themis Biosciences; Institut Pasteur	Merck
Ii-Key peptide COVID-19 vaccine	Generex Biotechnology	Pre-clinical	Generex	Generex
Recombinant vaccine	Vaxart	Pre-clinical	Vaxart	no information
LineaDNA	Takis Biotech	Pre-clinical	Takis Biotech	Takis Biotech
Ad26.COV2-S	Johnson & Johnson	Pre-clinical	Johnson & Johnson	Operation Warp Speed; Johnson & Johnson; BARDA
AdCOVID	Altimmune	Pre-clinical	University of Alabama at Birmingham	Altimmune
T-COVIDTM	Altimmune	Pre-clinical		Altimmune
Protein subunit vaccine	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre	Pre-clinical	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre	no information
V590	Merck; IAVI	Pre-clinical		BARDA
Adenovirus-based vaccine	ImmunityBio; NantKwest	Pre-clinical		Operation Warp Speed
AAVCOVID	Massachusetts Eye and Ear; Massachusetts General Hospital; University of Pennsylvania	Pre-clinical		Wyc Grousbeck; Emilia Fazzalari
Recombinant vaccine	Sanofi, Translate Bio	Pre-clinical		BARDA
HaloVax	Voltron Therapeutics, Inc.; Hoth Therapeutics, Inc.	Pre-clinical	MGH Vaccine and Immunotherapy Center
mRNA-based vaccine	Chulalongkorn University’s Center of Excellence in Vaccine Research and Development	Pre-clinical
HDT-301	University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp	Pre-clinical		University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp
gp96-based vaccine	Heat Biologics	Pre-clinical	University of Miami Miller School of Medicine
mRNA lipid nanoparticle (mRNA-LNP) vaccine	CanSino Biologics, Precision NanoSystems	Early research
Adenovirus-based vaccine	ReiThera; Leukocare; Univercells	Early research

Here are more COVID-19 vaccine trackers for reference: The Vaccine Tracker, Covid-19 Vaccine Tracker, Biorender, and Drugs Vaccines Tracker.

So there are many many vaccines in the pipeline and many resources to learn more about them. The Right Wire Report by no means can give ANY advice on Coronavirus vaccines. The only thing one can say is to educate yourself and learn as much as possible about vaccines and make your own informed decision with your doctor. Don’t play Vaccine Russian Roulette with your health.
In an interview, according to Bloomberg, Fauci, who has also been involved with White House’s “Operation Warp Speed” vaccine program, said it may take until well into 2021 for vaccines to reach much of the general public. “I would hope that by the time we get well into the second half of 2021 that the companies will have delivered the hundreds of millions of doses they have promised,” said Fauci. So patience will be needed.

RWR original article syndication source.